Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | BID | P55957 | 3/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.37 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9350709 | 0.98 | LIPG (0.50) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL13689141 | 0.87 | ADRA2B (0.42) | POLB | |
| SCHEMBL9192542 | 0.85 | LIPG (0.47) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL25786683 | 0.83 | LIPG (0.46) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL9184469 | 0.83 | LIPG (0.46) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL14191957 | 0.83 | TDP1 (0.47) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL31390779 | 0.83 | TDP1 (0.47) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL10408189 | 0.82 | LIPG (0.41) | LIPGNR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL28108556 | 0.82 | IDO1 (0.40) | — | |
| SCHEMBL9187793 | 0.81 | LIPG (0.40) | LIPGCYSLTR2CYSLTR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046340-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046340-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | LIPG 217/4885NR1H2 452/4885NR1H3 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.